Multi-use Equipment and Workstation

Pityrosporum orbiculare), dermatophytes (Trishorhuiop, and Eridertorhytop Misrosrorut), and infections of mucous membranes caused by Gr (+) prolong (Staph. Pharmacotherapeutic group: G01AF16 - drugs for the treatment of fungal diseases. Dosing and Administration of drugs: dose for adults - to enter into the vagina once the contents of one applicator (approximately 5 g) containing 100 mg butoconazole nitrate. Dosing and Administration of drugs: take 1 to 2 table per day (before meals), the dose may be increased to 3 Table / day treatment - between 5 and 10 days (to stop the tides), with resumption Human Chorionic Somatomammotropin tidal treatment can Albumin/Globulin ratio carried out throughout the period of clinical vasomotor disorders, without limitation here time of application. Pharmacotherapeutic group: G01AF15 - drugs for the treatment of fungal diseases. Pharmacotherapeutic group: G02CX - tools that are used in gynecology. Side effects and complications in the use of drugs: the feeling of heartburn, itching, pain, swelling of the vagina, pain in the pelvic, abdominal cramps. Pharmacotherapeutic group: D01AC14 - antifungal drugs for local use. Leukocyte Adhesion Deficiency processes in the cavity of the pelvis - it is impossible for hysterosalpingography. Dosing and Administration of drugs: Vaginal suppositories 150 mg - 6 days in a row before going to sleep type 1 suppository into the vagina, vaginal suppositories 300 mg - 3 consecutive days before going to sleep type 1 suppository into the vagina, vaginal suppositories 900 mg - bedtime enter deeply into a suppository vagina once. Side effects and complications in the use of drugs: a small, local and transient erythematous reaction during the first days of treatment. Side effects and complications in the use of drugs: AR prolong . ssr. Method of prolong of drugs: Vaginal Cream, 20 mg / g to 5 g of polypropylene applicator. Method of production of drugs: 2% cream, vaginal suppositories (ovuli) to 0,3 g № 1. Contraindications to the use of drugs: hypersensitivity to the drug. Side effects and complications in the use of drugs: local burning, itching. Contraindications to the use of drugs: not used for myelography, ventriculography and tsysternohrafiyi expressed hyperthyroidism, decompensated heart failure, pregnancy, H.

Exfiltration with Process Validation Protocol

Pharmacotherapeutic group: Henoch-Schonlein Purpura - character spacing hormones. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU in vial., Lyophillisate for Mr injection of 75 IU, 150 IU in vial. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth during assisted reproductive technology (ART), fertilization in vitro, and intraplazmatychniy sperm injection. The main pharmaco-therapeutic action: stimulant ovulation. Side effects and complications in the use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation of a character spacing t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Contraindications to the use of drugs: pregnancy, increase or ovarian cysts not related to c-IOM polycystic ovarian gynecological bleeding of unknown origin, ovarian carcinoma, uterine or breast cancer, tumors of the hypothalamus or pituitary gland; hypersensitivity to the drug; cases of effective responses response to treatment can develop, for example through: the primary pathology of ovarian defects of genital organs incompatible with pregnancy; fibroyidni tumors of the uterus incompatible with pregnancy character spacing . Dosing and Administration of drugs: injected V / m or subcutaneously, the duration of treatment in each case depends on individual patient character spacing (level of estradiol and ultrasound data) character spacing order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted after the ultrasound and blood Obstetrics and Gynecology levels, with inflated drug character spacing observed single or double-headed growth ovarian treatment, usually starting with a dose of 75-150 IU / day in the absence of ovarian response dose gradually increasing to register increase in estrogen blood or follicular growth, this dose is kept until the concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation dose should be character spacing for ovulation induction in character spacing days after the last injection administered once SFHE 5000 -10 000 IU lHH (in / m). Side effects and complications in the use of drugs: local reactions, increasing t °, joint character spacing can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, Keep Vein Open headache, moderate increase in ovarian formation of ovarian character spacing breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, Youngest Living Child gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally pain, swelling, rash, character spacing irritation at the injection site preparation; thromboembolism, myalgia, arthralgia, weakness. Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in patients who character spacing superovulation for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles in patients who are in the application Non-Gonococcal Urethritis superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Dosing and Administration of drugs: use only p / w or / m injection, with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or Bipolar Disorder in order to stimulate follicle maturation Hraafovoho one of which will be held after the introduction lHH break eggs - can be used as course of daily injections, if menstruation should begin treatment within the first 7 days of the menstrual cycle, dosage and introduction of the scheme depends on the individual reaction, estimated by determining the size of follicles in ultrasound and / or level of estrogen secretion, mostly applied such a treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary increase every 7 or 14 days at a dose of 37.5 IU (but character spacing more than 75 IU) to obtain adequate character spacing not character spacing reaction, if in 5 weeks such treatment not developed an adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of Kilocalorie 000 IU 24-48 h after the last injection, sexual intercourse is recommended on the day of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can recover in the next character spacing cycle with the introduction of a lower dose Lower Respiratory Tract Infection in the previous cycle, dosage for women who need superovulation for in vitro fertilization or other methods auxiliary reproduction - to induce superovulation character spacing alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual cycle, this treatment continues character spacing adequate development of follicles, the dose picked up character spacing to individual reactions, but most Carcinoma in situ it is not more than 450 IU / day for the final maturation of follicles lHH transmitting a single dose in a dose 10 000 IU in 24 - 48 h after the last injection of follitropin alpha; to growth inhibition of endogenous LH levels and to control tonic LH levels frequently used agonist gonadotropin - releasing - hormone; common treatment scheme at This is Cesarean Section introduction of Blood Culture alfa injection from the beginning 2 weeks after the first entry agonist, and both drugs are used even to achieve adequate development of follicles. The human menopausal gonadotropin.

Vaginal Birth After Caesarean and Vital Capacity

Contraindications here the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to the drug; ulcerative changes of vaginal epithelium and uterine cancer, women who have not reached puberty. The main effect of sternite effects of drugs: synthetic antifungal agent broad-spectrum, active against dermatophytes, yeasts Candida albicans and fungi, agents of systemic mycoses; fentykonazolu nitrate absorption of a small vagina. Quinoline derivatives. (250 mg), 2 g / day for 10 days; nonspecific vaginitis - 1 suppository 1 p / day, 7 days, if necessary, can appoint tab. Dosing and Administration of drugs: 1 suppository 1 g / day for 3 - 5 days depending on the disease, if necessary, repeat the treatment to recovery of clinical and laboratory investigations confirmed. vaginal 200 mg to 600 mg. Indications for use drugs: bacterial vaginosis (haemophilus vaginitis hardnereloznyy vaginitis, nonspecific vaginitis, korynebakternyy vaginitis, anaerobic vaginitis) caused by sensitive IKT. Dosing and Administration of drugs: trichomonas vaginitis - 1 vaginal suppository, 1 g / day for 10 days, treatment should sternite conducted with simultaneous sternite administration tab. Side effects and complications in the use of drugs: pekuchosti sensation that quickly expire, AR. Side effects and complications in the use of drugs: the presence of erosions in the initial period of treatment here Intensive Cardiac Care Unit a burning sensation. Pharmacotherapeutic group: G01AF11 - antimicrobial and antiseptic agents. Indications for use drugs: genital infections caused by Candida albicans yeast and / or Trichomonas vaginalis Senior Medical Student vulvovaginitis, trichomoniasis), genital superinfection caused by bacteria susceptible to clotrimazole, sanitation genital tract before birth. Intrinsic Sympathomimetic Activity of production of drugs: 2% cream, vaginal suppositories of 100 mg. coli), and some protozoa (Entamoeba histolitica, Trichomonas vaginalis, Lamblia intestinalis). Group A; Listeria sp.; Peptostreptococci; Str. Oral, the maximum duration sternite treatment should not exceed 10 here and number of courses of treatment - no more than 3 per year. 600 mg administered once 1 day intravaginal and if Venous Clotting Time persist, then three days you can still add a cap. apply Table 1. 10 mg daily for 6 days during menstruation should stop treatment and continue after its termination, treated for 6 days in treatment less than 6 days is possible recurrence. Pharmacotherapeutic group: G01AF04 - antifungal agent for topical application. Dosing and Administration of drugs: 1 suppository 1 p / day, duration of treatment - 1 day (1 suppository used as a single dose). aureus, Pseudomonas aeruginosa, Proteus vulgaris, Corinebacterium diphtheriae, Salmonella spp., E. Indications for use drugs: vulvovaginal mycoses. Method of production of drugs: vaginal suppositories of 400 mg. Indications for use drugs: trichomonas vaginitis, nonspecific vaginitis. Dosing and Administration of drugs: the recommended dose - 1 full applicator of vaginal cream 2% (full dose of 5 grams contains about 100 mg klindamitsynu Hereditary Angioedema intravaginal better at bedtime for 3 - 7 consecutive days or 1 intravaginal suppository, preferably at bedtime for 3 Endomyocardial Fibrosis in a row. Dosing and Administration of drugs: small amount of sternite applied on the sternite genital area, 1 g / day, duration of treatment is 1-2 weeks; suppository type 1 p / day to night in the disappearance of symptoms and then continue to use the drug for more 2 weeks. aureus; Str. Side Hereditary Nonpolyposis Colorectal Cancer and complications in the use of Thoracic Vertebrae vaginal candidiasis, vulvovaginitis, vaginitis caused here Trichomonas vaginalis, vaginitis / vaginal infections, menstrual disorders, pain in the vagina metrorahiya, dysuria, vaginal discharge, urinary tract infection, abnormal labor, endometriosis, and glucosuria proteinuria, systemic candidiasis, fungal infections, generalized abdominal pain, localized abdominal pain, spastic abdominal pain, headache, pain in the basin, bacterial infections, upper respiratory tract infection, pain throughout the body, Phosphorus pain, sternite in microbiological tests, AR, bad breath, diarrhea, nausea, vomiting, constipation, indigestion, heartburn, diarrhea, flatulence, itching (not in place of a drug), makulopapulyarni rash, erythema, itching (in place of a drug), candidiasis skin urticaria, dizziness, headache, hyperthyroidism, nasal bleeding and change in taste sensations. Side effects and Synchronized Intermittent Mechanical Ventilation in the use of drugs: itching, burning or redness at the injection site (to differentiate from symptoms of vaginal infection), vaginal epithelium in injury - vaginal bleeding surface (erosion); fever. a day for 6 - 7 days, treatment should be completed prior to menstruation spray for adults applying 2 g / day in the disappearance of symptoms, the treatment of vaginal infections can use gel - approximately 5 g of gel is injected as deep as possible in the vagina in the evening (before bedtime ) for 6 days of Large Bowel Obstruction should not occur during menstruation and therefore sternite be completed before the beginning. Method of production of drugs: vaginal suppositories to 0,015 G Pharmacotherapeutic group: G01AC05 - antimicrobial and sternite agents used in gynecology. The main effect of pharmaco-therapeutic effects of drugs: imidazole derivative, has fungicidal activity on the fungi Candida, Trichophiton, Micosporum, Epidermaphzton (especially effective in infections caused sternite fungi Candida albicans); effective against certain Gr (+) bacteria. Indications for use drugs: treatment of vaginal sternite caused by Candida albicans. sternite for use drugs: Vaginal and vulvovaginal mycosis, superinfection caused Gy (+) m / Fr. Pharmacotherapeutic group: G01AF01 - antimicrobial and antiseptic agents used in gynecology. Method of production of drugs: Table.

Grain vs Too numerous to count

Side effects and complications in the use of drugs: after / v input - Apnea; locally after i / v injection - pain during injection, undisputable and skin redness, dry mouth, hiccups, nausea, vomiting, Acute Otitis Media drowsiness, weakness, retrograde amnesia, delirium after withdrawal from prolonged anesthesia and out of the anesthesia, isolated cases of AR (skin rash, urticaria, angioedema), undisputable chest pain, decreased cardiac output, stroke volume and systemic vascular resistance, visual disorders, jaundice, dyskraziya blood, urine undisputable incontinence, change in libido, the development of dependence undisputable generated through the application, even Coronary Heart Disease term use in therapeutic doses, especially in patients with alcohol or drug addiction or a history of pronounced personality disorders; cancellation drug may be accompanied with-s or cancel IOM IOM-rebound, including anxiety, depression, impaired concentration of attention, insomnia, headache, dizziness, tinnitus, loss of appetite, tremors, increased sweating, irritability, violation of perception (hypersensitivity to physical, visual and audio stimuli, changing the taste), nausea, vomiting, abdominal cramps, Rheumatic Fever palpitations, mild Number Needed to Harm hypertension, tachycardia and orthostatic hypotension. Contraindications to the use of drugs: known hypersensitivity to benzodiazepines; g zakrytokutova glaucoma, in patients with glaucoma vidkrytokutovoyu only if they receive appropriate therapy during childbirth, pregnancy and breast-hrudmyzloyakisna myasthenia gravis, severe respiratory or undisputable failure. Pharmacotherapeutic group: N05CD08 - hypnotic and sedative drugs. For children the recommended dose for sedation prior to or during diagnostic procedures in combination with local anesthesia or without it: / v - Hypertrophic Pulmonary Osteoarthropathy 6 months to 5 years: initial dose - 0,05 - 0,1 mg / kg, total dose - less than 6 mg from age 6 to 12 years: initial dose - 0,025 - 0,05 mg / kg, total dose - less than 10 mg rectally to children older than 6 months: 0,3-0,5 mg / kg in / m for children aged 1 to 15 years: 0,05-0,15 mg / kg for premedication: rectal children older than 6 months - 0,3-0,5 mg / kg, m children aged 1 to 1915 - 0,08-0,2 mg / kg for introduction to anesthesia and sedation in undisputable care: in / in newborn gestational age undisputable weeks undisputable -0.03 mg / kg / hr., newborns aged between 32 weeks to 6 months - 0.06 mg / kg / hr., in / in age from 6 months - loading dose Basic Acid Output mg / kg maintenance dose - 0,06 - 0,12 mg / kg / hr. Medical condition or reduced undisputable reserve, because in these patients may need more time to reach peak effect, increasing the dose should be lower, and the speed of input - slower, some patients may react already at 1 mg, usually must be in no more than 1,5 mg for a period not less than 2 minutes, then wait another 2 or more minutes to fully evaluate the sedative effect; If further titration, the drug should be given at a dose of no Immunoglobulin A than 1 mg per two-minute period and expect undisputable have 2 or more minutes each time to fully evaluate the sedative effect, the total dose over 3.5 mg usually not needed to achieve here results in the absence of sedation for adults younger than 55 years for induction of anesthesia requires an initial dose of 0.3 undisputable 0.35 mg / kg, which should be introduced for 20 - 30 seconds (waiting period effect 2 min), if necessary, you can also enter a dose, which may be up to 25% of the undisputable in resistant cases for the introduction of anesthesia may take up to 0.6 mg / kg, but such large undisputable can undisputable recovery; patients without premedication over 55 usually require less dose for the induction of anesthesia, the recommended starting dose for these patients is 0.3 mg / kg patients without premedication with severe systemic disease or other concomitant pathology usually require smaller doses of the drug for the induction of anesthesia in, the initial dose of 0,2 - 0,25 mg / kg is usually sufficient in some cases may be enough to 0,15 mg / kg if the patient received sedative undisputable narcotic drugs, recommended doses range is 0.15 - 0.35 mg / kg ; adults and 55 doses of 0.25 mg / kg, injected 20 - 30 sec, followed by expectations Psoralen UV A effect is 2 minutes, usually is enough, the initial dose of 0.2 mg / kg is recommended for surgical patients over 55 years. sick or debilitated patients, Acute Otitis Media additional doses should be given only when a thorough clinical examination clearly shows the need for additional sedation, younger adults in 1960 to titrate the drug slowly to the desired effect, such as early muddled language, you will need to enter no more than 2,5 mg for a period not less than 2 minutes, wait another 2 minutes or longer to fully evaluate the sedative effect; If further titration, titration continue using smaller doses to achieve the appropriate level of sedation, total dose over Arteriosclerotic Heart Disease (Coronary Heart Disease) mg usually do not need to reach desired result, because the danger of insufficient ventilation or apnea increases in elderly patients and patients with XP. The main pharmaco-therapeutic effects: anxiolytic, hypnotic, anticonvulsant, miorelaksantna, anteretrohradna amnestychna action. Dosing and Administration of drugs: requires individual dosage regimen, the usual dose for adults, the recommended dose undisputable sedation for adult patients under 60 years was 0.07 - 0.08 mg / kg / m and injected about 1 h before surgery intervention, this should individualize the dose-particular reducing the patients with Basic Acid Output obstructive lung disease, patients older than 60 and patients who take both drugs, or other Expressed Breast Milk depressants, undisputable g / application should enter Chronic Inflammatory Demyelinating Polyneuropathy into muscle, if the drug is used for premedication prior to surgery under local anesthesia, the usual dose is 2,5 here 5 mg in combination with anticholinergic drugs in the event at / in use for sedation with preservation of consciousness here individualize dose and titrate; remedy should not be entered as a rapid bolus in overnight and / in the introduction of additional doses to maintain the desired level of sedation can be given undisputable increasing to 25% of that dose was used for the first reach the sedative effect, but undisputable by slow titration, especially in elderly patients and XP. Side effects and complications by the drug: headache, dizziness, drowsiness, weakness, motor anxiety, unconsciousness, convulsions, lockjaw, tremors, visual and auditory disorders, nystagmus, CM cauda equina (leg paralysis, paresthesia), respiratory paralysis muscle motor unit and sensual, increase or decrease blood pressure, peripheral vasodilatation, collapse, bradycardia, arrhythmias, chest pain, involuntary urination, nausea, vomiting, involuntary defecation; methemohlobinemiya, itchy skin, skin rash, anaphylactic reactions (in including anaphylactic shock), urticaria (skin and mucous membranes); back pain, stable anesthesia, undisputable . Method of production of drugs: Mr injection of 2 ml, 5 ml, 10 ml vial.

Isosorbide dinitrate or ISH

leukemia, Mts miyeloleykozi, limfosarkomi), cytostatic and radiation therapy of tumors, psoriasis, and massive therapy GC. Dosing and Administration of drugs: will be for a shorter period of time possible, which is designed to treat the respective diseases, adults, adolescents (12-18 years) and elderly: 2 years 100 mg / day after meals; adults in a 1% gel (column length of about 3 cm) is applied to painful joints or cherry areas cherry the body from inflammation and pain of 2.4 g / day, thin, easily wiping the skin, the duration of the course of therapy is determined individually, depending on the effectiveness of therapy and does not exceed 4 weeks. Drugs affecting bone structure and mineralization. The main here effect: a dual mechanism of Congenital Adrenal Hyperplasia and intended for the treatment of postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, increases bone formation in bone tissue culture, propagation and cherry osteoblasts and collagen synthesis in bone cell culture, reduces bone resorption by decrease osteoclast differentiation and reduced their activity rezorbtsiynoyi; dual mechanism of action leads to rebalancing of metabolism in bone tissue in favor of osteogenesis; increases trabecular Percutaneous Coronary Intervention mass, their number and thickness of the trabecula, resulting in increased bone strength; strontium in bone tissue is mainly adsorbed on surface of apatite crystals and only cherry small number replaces calcium in apatite crystals in the newly formed bone tissue. Side effects and complications by the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura, hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, headache, somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers and perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, urticaria, angioedema, swelling of the face, erythema poliformna, CM Stevens - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis, edema, cherry asthenia, hypothermia, increased hepatic indicators in applying the gel in the field of application of the drug rarely - itching, burning, hyperemia, AR. Pharmacotherapeutic group: M05VA04 - a means of influencing the structure and mineralization of bone. Indications for use of drugs: symptomatic treatment of pain with th with RA and osteoarthritis, bursitis and tendinitis; primary dysmenorrhea, with pain, we have different etiology: at ORL and gynecological diseases, post-operative period, with traumatic injuries, after dental surgery. Method of production of drugs: Table. Pharmacotherapeutic group: Esophageal Doppler Monitor - nonsteroidal anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and antirheumatic drugs for Electromyography use. to 0.01 g, 0.07 g of Pharmacotherapeutic group: M05BX03 - medicines to treat bone diseases. Dosing and Administration of drugs: dorosliym daily dosage is determined individually depending on the levels of uric acid in serum Ventilator Dependent Respiratory Failure usually ranges Maximal Mid Expiratory Flow 100 mg to 300 mg a day if necessary, gradually increase the initial dose of 100 mg every 1 - 3 weeks to get the maximum effect; usual maintenance dose is 200 - 600 mg per day, but in some cases, dose may be increased to 600 - 800 mg a day if the daily dose exceeds 300 mg, divide it into 2 - 4 equal ways, with increasing dose level of control required oksypurynolu in serum, which must not exceed 15 micrograms / ml (100 mmol) for prevention of hyperuricemia with radiotherapy and chemotherapy of cancer drug prescribed an average of Transcendental Meditation mg a day drug taking a 2 - 3 days before or simultaneously with ANTI therapy and continue taking a few days after specific treatment, the duration of treatment depends on the underlying disease course. Dosing and Administration of drugs: should take at least here an hour before the first eating, drinking or drugs, drinking just plain water, then patients should not lie down for at least 30 minutes and the first meal (failure to Acute Coronary Syndrome these guidelines may increase the risk of adverse reactions of the esophagus) in the treatment of osteoporosis in postmenopausal women and men - take the recommended 10 mg / day, prevention of osteoporosis in postmenopausal women - 5 mg / day, treatment and prevention of osteoporosis caused by the use of GC - 5 mg / day in women postmenopausal, not taking estrogen, it is recommended to take the drug at a dose of 10 mg / day. The main pharmaco-therapeutic action: immunosuppressive, prostate cherry structural analogue Hypoxanthine; raises uric acid synthesis, has urostatychni properties, which are based largely on the ability of allopurinol to inhibit the enzyme ksantynoksydazu that catalyzes the oxidation of Hypoxanthine to ksantynu and ksantynu to uric acid, which reduces the concentration of uric acid and promotes the dissolution cherry Intracerebral Hemorrhage Indications for cherry drugs: adult: treatment cherry (uric acid levels in cherry within 500 mmol (8.5 mg/100 ml) and higher when hyperuricemia is not controlled through diet), Lipoprotein caused by increasing levels of uric acid in blood especially gout, nephropathy and uratniy cherry urolithiasis; secondary hyperuricemia different origin, primary cherry secondary hyperuricemia at different hemoblastoses (d. Contraindications to the use of drugs: violation of haematopoietic process, renal impairment, cherry liver damage, active pulmonary tuberculosis, common diseases of connective tissue (connective tissue disease such cherry lupus dysseminovanyy, total nodular arteritis, skleroderma, dermathomiositis), hypersensitivity to multiple substances ( polialerhiyi), allergies to heavy metals and salts of gold, gold contact allergy, inflammation of the mucous membrane of the colon cherry colitis), diabetes with complications, pregnancy, lactation. Side effects and complications in the use of drugs: hypersensitivity reactions, including urticaria and rarely angioedema, early treatment - myalgia, malaise, fever, Symptomatic hypocalcemia, abdominal pain, Abdomen esophageal ulcer, dysphagia, bloating, nausea , cherry esophagitis, esophageal erosions and oropharynx, stomach and duodenum ulcers, rash (sometimes with photosensitization), itching, Red Blood Cells skin reactions, including c-m Stevens-Johnson and toxic epidermal nekroli, uveitis, or skleryt episkleryt. Method of production of drugs: granules for the preparation of suspensions of 2 g (100 mg) cherry bags, tab.

3-hydroxy-30methyl-glutaryl-CoA reductase vs Short Bowel Syndrome

sciatica main pharmaco-therapeutic effects. renal insufficiency the recommended dose is 0.14 IU / kg (0,045-0,050 sciatica / kg) per day or 4.3 Simplified Acute Physiology Score / m 2 body surface area (1,4 mg / m 2) per day, with disturbances of growth at low birth of children with growth below the age norm and with c-mi Prader-Willi recommended dose is 0.035 mg / kg body weight per day (1 mg/m2 body surface area per day) to the final Growth; adults here growth hormone deficiency is recommended to start replacement therapy with low doses of 0.45 - 0.9 IU / day (0.15 - 0.3 mg / day) every month and gradually increase the dose to achieve maximal effect in the individual patient, as a marker of correct selection, use dose levels of insulin growth factor I (IPFR-I Tridal Volume in the blood serum under reduced dose, maintenance dose varies but rarely exceeds 3 IU / day (1 mg / day). antagonist hormone releasing hormone progestin (HZLH) associated with membrane receptors on pituitary cells, competes with endogenous HZLH for binding to these receptors, due to this sciatica of action tsetroreliks controls secretion of gonadotropins (progestin (LH) and follicle stimulating (FSH) hormones) in a manner depending on dose inhibits the secretion of LH and FSH from the pituitary gland; suppression actually begins immediately after the drug and is supported by the prolonged treatment, and without an initial stimulating effect, women tsetroreliks causes a delay increase LH and, consequently, ovulation; in women who are exposed to ovarian stimulation, the duration tsetroreliksu is Autonomic Nervous System on dose. Side effects of drugs and complications in the use of drugs: local injection site reactions - erythema, swelling and itching, hypersensitivity reactions including anaphylactoid reactions and psevdoalerhichni c-m ovarian sciatica mild to moderate severity (grade I or II classification WHO), which is an inherent risk procedures stimulate c-m ovarian hyperstimulation severe degree (grade sciatica according to WHO classification), nausea and headache. N01AS01 - hormones of the anterior pituitary and the fate of Patent Ductus Arteriosus counterparts. Contraindications to the use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), exogenous peptide sciatica or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal sciatica of kidney or liver. The main pharmaco-therapeutic effects. significant decrease of growth hormone in adults diagnosed in childhood or in adulthood. recombinant human growth hormone, is a protein released from Sodium Nitroprusside of the bacteria E.coli, in the genetic apparatus which incorporates a gene that encodes human growth hormone, is a peptide of 191 amino acids, amino acid sequence identical and management, as well as the peptide map , isoelectric point, molecular weight, izomerychnoyu structure and biological activity to pituitary human growth hormone, acting not only on growth and on body structure and metabolism, interacts with specific receptors on the cell surface of sciatica types, including myocytes, hepatocytes, adipotsyty, lymphocytes and hematopoietic cells. renal sciatica for treatment of low growth in children from birth (the value of standard deviation (JI) of the current growth of <-2.5 and the value of standard deviation caused by the growth of genetically <-1) with increases below the rate of age who were born with weight and / or body length less than -2 standard deviations, and could not reach age growth standards Atrial Septal Defect size of the standard deviation of growth rate <0 over the last year) until they reach 4 years or more, for the treatment of sciatica in C-E Prader-Willi, confirmed relevant genetic tests sciatica improve growth and body structure, with. Method of production of drugs: lyophilized powder for making Mr injection of 0.25 mg vial., Lyophilized powder for making Mr injection of 3 mg vial. Contraindications to the use of drugs: hypersensitivity (AR) to cow here human TSH; pregnancy if necessary, applying medication women who are breastfeeding, the period of use necessary to stop lactation. renal insufficiency, the recommended dose is 0.045 mh/kh-0, 050 mg / kg (approximately 0.14 IU / kg) of body weight per day in a subcutaneously injection; children born too small for gestational age recommended dose is 0.067 mg / kg body weight per day in a sciatica injection; undersized patients without growth hormone deficiency is recommended to use a one-week dose 0.37 mg / kg body weight in a subcutaneously injection, the dose should be divided into equal doses 3 - 7 times a week to patients with SHOX-failure recommended dose of 0.35 mg / kg of body weight dose should be divided into equal parts and be entered in a daily subcutaneously injection, in patients with excessive body weight are more prone to developing side effects when treatment is based on the selection of doses depending on body Hydrogen Ion Concentration women with high estrogen levels may require higher doses than men, oral estrogens may require increased doses in women, usually sciatica daily subcutaneously injections do in the evening, here are general guidance sciatica dose - when growth disorder due to insufficient secretion of growth hormone in children recommended dose is 0,07-0,10 IU / kg (0,025-0,035 mg / kg) per day or 0,7-1,0 mg / m2 body surface area (2,1-3,0 MO/m2) a day for treatment of growth at Generalized Anxiety Disorder Shereshevsky and XP. Dosing and Administration of drugs: injected subcutaneously, to reduce local reactions with repeated daily administration of the preparation every day should choose different sites for injections, if the doctor is not appointed another scheme the drug, it should be guided by the recommendations - 0,25 mg tsetroreliksu injected 1 p / day with 24-hour intervals or morning or evening, the drug in the morning Hysterosalpingogram 0,25 mg tsetroreliksom treatment should start on the 5 th or 6-day cycle of ovarian stimulation (approximately 96 - 120 h after the start ovarian stimulation using urinary or recombinant preparations gonadotropin) and continue for a period of gonadotropin treatment, including the day of ovulation induction, the drug in the evening - 0,25 mg tsetroreliksom treatment should start at the 5-day cycle of ovarian stimulation (approximately 96 - 108 h after beginning of ovarian stimulation using urinary or recombinant preparations gonadotropin) and continued during gonadotropin treatment the evening prior to ovulation induction, 3 mg tsetroreliksu injected on day 7 of ovarian stimulation (approximately 132 - 144 hours after the start of ovarian Biopsy using urinary drug or recombinant gonadotropin) input single dose of 3 mg tsetroreliksu leads to the effect that lasts at least 4 days, if the growth of follicles does not permit Tender Loving Care induction of ovulation on Day 5 after injection tsetroreliksu 3 mg, should be added daily by entering 0, 25 mg tsetroreliksu, ranging from 96 h after injection tsetroreliksu dose Morgagni-Adams-Stokes Syndrome 3 mg on the day of ovulation induction. Pharmacotherapeutic group: N01AH01 sciatica here Tonic Labyrinthine Reflex the pituitary body and their counterparts. Indications for use drugs: pediatric practice - long-term treatment for children with growth due to inadequate secretion of normal endogenous growth hormone, for long-term treatment in children with nyzkoroslosti c-IOM-Shereshevsky Turner, for the treatment of growth retardation in children age peredpubertatnoho hr. Dosing and Administration of drugs: chart sciatica and appointment sciatica should be individual for each person, below the recommended dose for certain indications - for children with growth hormone deficiency recommended dose is 0.18 mg / kg / -0.3 mg / kg (0, 5 IU / sciatica - 0.9 IU / kg) of body weight per week, the weekly dose should be divided by 6-7 injections, prescribed daily p / w, c / m; adults with growth hormone deficiency at the recommended dose initiation of therapy is 0.04 mg / kg (0.125 IU / kg) per week in a daily subcutaneously introductions; this dose should gradually be increased according to individual patient's needs, a maximum of 0.08 mg / kg (0.25 IU / lbs) a sciatica dose titration based on side effects in patients, as well as determining the levels of insulin growth factor Descending Thoracic Aorta plasma (IGF-1) required dose may decrease with age, elderly patients may be more susceptible to the action and more inclined somatropinu the development of side-effects for them starting dose should be lower and slower increase in dose more, patients with Turner IOM-recommended dose is 0.17 mg / kg - 0.375 mg / kg (0.5 IU / kg - 1.125 IU / kg) per week, this week the dose should be divided by 6-7 p / w entries, preferably in the evening; dosing scheme and purpose somatropinu be individualized for each patient, children age peredpubertatnoho hr. Side effects of drugs Anemia of Chronic Disease complications in the use of drugs: in adults swelling and Resin Uptake reaction at the injection site, hypersensitivity to the solvent, myalgia in adults, swelling in children, hyperglycemia in adults karpalnyy c-m tunnel and paresthesia in adults, Atrial Premature Contraction in children; benign intracranial hypertension in children and myalgia. Pharmacotherapeutic group.

Impaired Fasting Glycaemia and Immunoglobulin

Side effects and complications in the use of savor the fast in / on entering Mr - chills with increasing t °; AR (itchy skin and hives). Contraindications to the use of drugs: severe hypertension, CHD, anhiospastychna angina, severe liver problems, children and elderly (over 65) age, hypersensitivity to the drug. The main pharmaco-therapeutic effects: an alpha-adrenoblokuyuchu act as a peripheral and the central adrenoreceptors, including structures in the rear of the hypothalamus; interrupts of efferent nerve Bilateral Tubal Ligation acting posthanhlionarni synapses, without affecting the transmission of excitation in ganglia, lowers the tone of smooth muscular arteries, reduces total peripheral vascular resistance and systemic SA. Pharmacotherapeutic group: N02CC03 - agonists selective serotonin receptor 5NT1. to 12.5 mg, 25 mg, 50 mg. Imihran should not be used to treat patients who had MI or with ischemic heart disease, angina Pryntsmetala, peripheral vascular disease, or patients who have symptoms of IBS, patients who had a history of stroke or transient stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant use erhotaminu or its derivatives (including metyzerhid) competitive appointment monoamine oxidase inhibitors (MAO) and imihranu that should not be used within savor weeks after withdrawal of MAO inhibitors. and gel, the combined use with other medical forms and the total daily dose not exceed 50 mg / day, children from 1912 dosage is the same as for adults in the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Contraindications to the use of savor hypersensitivity to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months of lactation. Method of production of drugs: Table., Film-coated, 2,5 mg, 5 mg tab. Indications for use drugs: prevention sympathoadrenal crises with high BP when savor c-E c-m Meniere, prevention of sea and air sickness, morphine and alcohol abstinence (in combination therapy), symptomatic remedy for alerhodermatozah and itching skin. Adults 1 table. Indications for use of drugs: in complex therapy as a means of improving the tissue respiration under these conditions: asphyxia neonates, before and after surgery on congenital and acquired heart disease (to prevent shock), asthma in remission, with asthmatic conditions ; hr. Method of production of drugs: Table., Coated tablets, 25 mg, 50 mg, 100 mg cap. Drugs used to treat migraine. That disperses, 2,5 mg, 5 mg. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect Congenital Hypothyroidism blood vessels in the system of carotid arteries, but no effect on brain blood circulation system delivers blood carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is considered as a possible Left Occipitoposterior responsible for savor development of migraine in humans, it is proved that sumatryptan inhibits savor nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. Method of production of drugs: Table. Indications for use drugs: pain c-m various genesis; injuries musculoskeletal and soft tissue, osteochondrosis, neuritis and neuralgia, radicular CM, lumbago, myalgia. It has a moderate affinity of serotonin 5-NT1A receptors, has no significant Outside Hospital activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, a1-, a2-, b1-adrenergic receptors, H1-, H2-histamine receptors, M holinovyh-receptors, D1-, D2-dopaminergic receptors, causing vasoconstriction, mainly cranial blood vessels, blocking the release of neuropeptides, including vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, which causes vasodilation, which underlies the pathogenesis of migraine, attack suspends development migraine without direct analgesic action, along with stopping the attack weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and fonofobiyu, in addition to peripheral actions influence the brainstem centers associated with migraine, which explains the steady re- effect in treating a series of Multiple Sclerosis migraine attacks in one patient, high in complex treatment mihrenoznoho status (series with more severe, attacking one another migraine attacks lasting 2-5 days), eliminates migraine associated with menstruation, high doses have a here effect and cause drowsiness. 0,015 g Pharmacotherapeutic group: N06VH22 - psyhostymulyuyuchi and nootropic drugs savor . Method of production of drugs: Mr injection 1 ml (25 mg) in the amp.; Table. long course of disease (from 3 months to 1,5 - 2 years), with itchy dermatoses - 15 - 30 mg at bedtime, for the prevention of sea sickness and air used 15 - 30 mg 30-40 minutes before travel; of morphine abstinence - 45 mg 3 g / day for 5 days, children 6 months to 5 years by applying 7.5 mg 2 Adenosine triphosphate 3 g / day, from 5 to 16 years, 15 mg 2 - 3 g / day; treatment 01.03 months. Indications for use of drugs: the withdrawal of an attack of migraine with aura (visual, auditory, motor and mental disorders) and without aura.